Immunoglobulin Heavy/Light Chain Ratios Improve Paraprotein Detection and Monitoring, Identify Residual Disease and Correlate With Survival in Multiple Myeloma Patients

Leukemia - United Kingdom
doi 10.1038/leu.2013.25
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Prognostic Utility of Serum Free Light Chain Ratios and Heavy-Light Chain Ratios in Multiple Myeloma in Three PETHEMA/GEM Phase III Clinical Trials

PLoS ONE
Multidisciplinary
2018English

Clinical Characteristics and Prognostic Factors in Multiple Myeloma Patients With Light Chain Deposition Disease

American Journal of Hematology
Hematology
2017English

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

JAMA Oncology
Cancer ResearchOncology
2017English

Promiscuous Translocations Into Immunoglobulin Heavy Chain Switch Regions in Multiple Myeloma

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1996English

Genomic Aberrations and Survival of Patients With Light-Chain-Only Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2011English

Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite™ Assay) – Benefit for Stratification of Multiple Myeloma?

Klinicka Onkologie
Oncology
2015English

Improving Minimal Residual Disease Detection in Precursor B-All Based on Immunoglobulin-Κ and Heavy-Chain Gene Rearrangements

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2008English

Serum Immunoglobulin Free Light Chain Measurements and Heavy Chain Isotype Usage Provide Insight Into Disease Biology in Patients With POEMS Syndrome

American Journal of Hematology
Hematology
2010English

PRDI-BF1 and PRDI-BF1β Isoform Expressions Correlate With Disease Status in Multiple Myeloma Patients

Hematology Reports
Hematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy